CAMBRIDGE, Mass., May 20, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative drug discovery and development company, today announced that data from its Hsp90 chaperone and Hedgehog pathway inhibitor programs will be presented during the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago, Ill. from June 4 through June 8, 2010.
The schedule of presentations from Infinity's anti-cancer programs is as follows:
| Saturday, June 5, 2010: 2:00 – 6:00 p.m. CDT |
| Poster Session Title: Hedgehog pathway inhibition impedes ovarian cancer xenograft growth in the adjuvant and maintenance settings |
| Presenter: Bo Rueda, Ph.D., Associate Professor, Department of Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School and Associate Director, Vincent Center for Reproductive Biology, Massachusetts General Hospital |
| Location: S Hall A2 |
| Sunday, June 6, 2010: 8:00 a.m. – 12:00 p.m. CDT |
| Poster Session Title: Combined hedgehog and epidermal growth factor receptor (EGFR) inhibition in a direct patient tumor model (DPTM) of head and neck squamous cell cancer (HNSCC) |
| Presenter: Antonio Jimeno, M.D., Ph.D., Associate Professor, Division of Medical Oncology and Director, Head and Neck Cancer Medical Oncology Program and Developmental Therapeutics/Pharmacodynamics Laboratory, University of Colorado Denver School of Medicine |
| Location: S Hall A2 |
| Monday, June 7, 2010: 3:00 – 5:30 p.m. CDT |
| Poster Session Title: Association between Anaplastic Lymphoma Kinase rearrangements (rALK) and the clinical activity of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in patients with non-small cell lung cancer (NSCLC) |
| Presenter: Lecia V. Sequist, M.D., M.P.H., of Massachusetts General Hospital Cancer Center and Assistant Professor of Medicine, Harvard Medical School |
| Location: E Hall D2 |
About Infinity Pharmaceuticals, Inc.
Infinity is an innovative drug discovery and development company seeking to discover, develop, and deliver to patients best-in-class medicines for difficult to treat diseases. Infinity combines proven scientific expertise with a passion for developing novel small molecule drugs that target emerging disease pathways. Infinity's programs in the inhibition of the Hsp90 chaperone system, the Hedgehog pathway and fatty acid amide hydrolase are evidence of its innovative approach to drug discovery and development. For more information on Infinity, please refer to the company's website at http://www.infi.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including statements regarding the presentation of data from the Company's Hsp90 chaperone and Hedgehog pathway inhibitor programs. These statements involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such statements are subject to numerous factors, risks and uncertainties that may cause actual events or results to differ materially from the company's current expectations. For example, there can be no guarantee that Infinity's strategic alliance with Purdue and Mundipharma will continue for its expected term or that they will fund Infinity's programs as agreed, that any product candidate Infinity is developing will successfully complete necessary preclinical and clinical development phases, or that development of any of Infinity's product candidates will continue. Further, there can be no guarantee that any positive developments in Infinity's product portfolio will result in stock price appreciation. Management's expectations could also be affected by the risks and uncertainties described under the caption "Risk Factors" included in Infinity's quarterly report on Form 10-Q filed with the Securities and Exchange Commission on May 6, 2010. Any forward-looking statements contained in this press release speak only as of the date hereof, and Infinity expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.